Last updated 4 days ago

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

1800 patients around the world

Available in Puerto Rico, Spain, United States, Mexico, Argentina

Eli Lilly and Company

41Research sites

1800Patients around the world

This study is for people with

Obesity

Cardiovascular disease

From 18 Years

All Gender

: Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²).
Have established cardiovascular (CV) disease with at least 1 of the following:
- prior myocardial infarction
- prior ischemic or hemorrhagic stroke, or
- symptomatic peripheral arterial disease
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.

: Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening.
Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
Have a prior or planned surgical treatment of obesity.
Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening.
Have Type 1 diabetes.
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had pancreatitis.